Artificial Intelligence & Medical Products

2024

Open publication workspace · Sign in to read the full PDF.

AI-generated summary

1) This document matters because it outlines how FDA centers (CBER, CDER, CDRH, and OCP) collaborate to establish a cohesive, risk-based regulatory framework for artificial intelligence across the entire medical product life cycle.
2)
- Joint FDA agency initiatives for fostering cross-center collaboration, stakeholder engagement, and international alignment regarding AI use in healthcare.
- Development of supportive regulatory approaches, guidances, and predictive frameworks to safely manage AI-enabled devices, drugs, and biologics.
- Strategic promotion of harmonized standards, best practices, quality assurance, and ongoing research projects addressing AI performance and bias mitigation.
3) Tags: artificial intelligence, FDA, medical products, regulation, health equity

Check the original publication for accuracy and context.